{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:05:19Z","timestamp":1783573519467,"version":"3.55.0"},"reference-count":65,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Patient care and control of inflammatory disorders, such as psoriasis, can be improved by model-informed precision dosing (MIPD) techniques based on population pharmacokinetic\/pharmacodynamic (PK\/PD) models. Clinical dose selection decisions based on MIPD strategies need to take account of the uncertainty associated with the individual PK\/PD model parameters, which is determined by the quantity of individual observational data collected in clinical practice. Methods: The aim of this study was to propose an approach for personalized dosage regimens of secukinumab (SCK) in 22 Spanish patients with plaque psoriasis, whose severity level was considered moderate to severe, taking into account the uncertainty associated with individual parameters in a population-based PK\/PD model. Results: The link between SCK serum concentrations and Psoriasis Area and Severity Index (PASI) scores was explained using an indirect response model. A maximum inhibition (Imax) drug effect model was applied to limit the progression of psoriatic skin lesions within the turnover PD mechanism, which explains the changes in PASI scores during treatment. A first-order remission rate constant for psoriatic lesions (kout = 0.11 day\u22121) was estimated. Conclusions: According to the MIPD strategy, 50% of patients would require an optimized regimen and 14% would require an intensified dosage regimen in comparison to current clinical treatment. This research has shown its usefulness as a tool for choosing individualized SCK dosage regimens in patients with long-lasting plaque psoriasis to improve the probability of achieving satisfactory response levels.<\/jats:p>","DOI":"10.3390\/pharmaceutics16121576","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T08:40:10Z","timestamp":1733820010000},"page":"1576","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2065-7188","authenticated-orcid":false,"given":"Karine","family":"Rodriguez-Fernandez","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain"},{"name":"Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia\u2013University of Valencia, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4799-9076","authenticated-orcid":false,"given":"Javier","family":"Zarzoso-Foj","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain"},{"name":"Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia\u2013University of Valencia, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Saez-Bello","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Doctor Peset University Hospital, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Mateu-Puchades","sequence":"additional","affiliation":[{"name":"Dermatology Service, Doctor Peset University Hospital, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-1590","authenticated-orcid":false,"given":"Antonio","family":"Martorell-Calatayud","sequence":"additional","affiliation":[{"name":"Dermatology Service, Hospital Manises of Valencia, 46940 Manises, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4956-0247","authenticated-orcid":false,"given":"Matilde","family":"Merino-Sanjuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain"},{"name":"Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia\u2013University of Valencia, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2148-3163","authenticated-orcid":false,"given":"Elena","family":"Gras-Colomer","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Hospital Manises of Valencia, 46940 Manises, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4387-1987","authenticated-orcid":false,"given":"Monica","family":"Climente-Marti","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Doctor Peset University Hospital, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3388-5023","authenticated-orcid":false,"given":"Victor","family":"Mangas-Sanjuan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain"},{"name":"Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia\u2013University of Valencia, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-015-0143-7","article-title":"Secukinumab: A review in moderate to severe plaque psoriasis","volume":"16","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.disamonth.2018.06.001","article-title":"Biologics for the primary care physician: Review and treatment of psoriasis","volume":"65","author":"Schadler","year":"2018","journal-title":"Disease-a-Month"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","article-title":"Update on psoriasis immunopathogenesis and targeted immunotherapy","volume":"38","author":"Mahil","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: Toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","unstructured":"(2024, September 17). EMA: COSENTYX-EPAR-product information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/1203475419843118","article-title":"Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis","volume":"23","author":"Phung","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jdv.16180","article-title":"Real-world evidence of secukinumab in psoriasis treatment\u2014A meta-analysis of 43 studies","volume":"34","author":"Augustin","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/bjd.18981","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: A prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"183","author":"Yiu","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1007\/s12325-022-02155-9","article-title":"Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan(\u00ae) Databases","volume":"39","author":"Leonardi","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jid.2023.04.009","article-title":"Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment\u2014A Nationwide Cohort Study","volume":"143","author":"Thein","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/exd.12710","article-title":"Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis","volume":"24","author":"Reich","year":"2015","journal-title":"Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: A randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Fern\u00e1ndez, K., Mangas-Sanju\u00e1n, V., Merino-Sanju\u00e1n, M., Martorell-Calatayud, A., Mateu-Puchades, A., Climente-Mart\u00ed, M., and Gras-Colomer, E. (2022). Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030654"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/17512433.2023.2259300","article-title":"Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling","volume":"16","author":"Liu","year":"2023","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0001-7310(12)70009-1","article-title":"Practical management of ustekinumab in moderate-severe psoriasis","volume":"103","author":"Notario","year":"2012","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tyson, R.J., Park, C.C., Powell, J.R., Patterson, J.H., Weiner, D., Watkins, P.B., and Gonzalez, D. (2020). Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00420"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients with Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.3748\/wjg.v27.i37.6231","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring","volume":"27","author":"Albader","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1053\/j.gastro.2022.01.044","article-title":"Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"115421","DOI":"10.1016\/j.addr.2024.115421","article-title":"Model-informed precision dosing: State of the art and future perspectives","volume":"215","author":"Minichmayr","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/978-1-4939-3283-2_19","article-title":"Modeling and Simulation Tools: From Systems Biology to Systems Medicine","volume":"Volume 1386","author":"Schmitz","year":"2016","journal-title":"Systems Medicine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/cpt.3365","article-title":"Recent Advances Addressing the Challenges of Precision Dosing","volume":"116","author":"Minichmayr","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115721","DOI":"10.1016\/j.psychres.2024.115721","article-title":"Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling","volume":"333","author":"Carracedo","year":"2024","journal-title":"Psychiatry Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Fern\u00e1ndez, K., Reynaldo-Fern\u00e1ndez, G., Reyes-Gonz\u00e1lez, S., de Las Barreras, C., Rodr\u00edguez-Vera, L., Vlaar, C., Monbaliu, J.M., Stelzer, T., Duconge, J., and Mangas-Sanjuan, V. (2024). New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK\/PD model. Biomed. Pharmacother.=Biomed. Pharmacother., 170.","DOI":"10.1016\/j.biopha.2023.115977"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/cpt.3197","article-title":"Beyond Population-Level Targets for Drug Concentrations: Precision Dosing Needs Individual-Level Targets that Include Superior Biomarkers of Drug Responses","volume":"116","author":"Polasek","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/0091270008329556","article-title":"Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis","volume":"49","author":"Zhu","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.2033","article-title":"Extrapolating Pharmacodynamic Effects From Adults to Pediatrics: A Case Study of Ustekinumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis","volume":"109","author":"Zhou","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_38","unstructured":"(2022). Medical Laboratories\u2014Requirements for Quality and Competence (Standard No. ISO 15189)."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: Part 3-introduction to pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/978-1-62703-050-2_21","article-title":"Mechanism-based pharmacodynamic modeling","volume":"929","author":"Reisfeld","year":"2012","journal-title":"Computational Toxicology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10928-008-9088-2","article-title":"Approaches to handling pharmacodynamic baseline responses","volume":"35","author":"Dansirikul","year":"2008","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"ref_44","unstructured":"Lixoft (2024, July 25). Monolix Suite 2024R1 (2024). Available online: https:\/\/lixoft.com\/products\/monolix\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1038\/psp.2013.56","article-title":"Application of ggplot2 to Pharmacometric Graphics","volume":"2","author":"Ito","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_46","unstructured":"R Core Team (1999\u20132024). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: http:\/\/www.R-project.org\/."},{"key":"ref_47","unstructured":"(2024, January 25). Monolix 2024R1 User Guide. Available online: https:\/\/monolix.lixoft.com\/single-page\/."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/psp4.12286","article-title":"Confidence and Prediction Intervals for Pharmacometric Models","volume":"7","author":"Bonate","year":"2018","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_49","unstructured":"Lixoft (2024, July 25). Simulx 2024R1 (2024). Available online: https:\/\/simulx.lixoft.com\/."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0091270009343695","article-title":"Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis","volume":"50","author":"Zhou","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cpdd.103","article-title":"A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study","volume":"3","author":"Salinger","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jcph.312","article-title":"Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis","volume":"54","author":"Tham","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cts.12725","article-title":"Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study","volume":"13","author":"Pan","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/bcp.14280","article-title":"Exposure-response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials","volume":"86","author":"Kerbusch","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Fern\u00e1ndez, K., Zarzoso-Foj, J., Saez-Bello, M., Mateu-Puchades, A., Martorell-Calatayud, A., Merino-Sanjuan, M., Gras-Colomer, E., Climente-Mart\u00ed, M., and Mangas-Sanjuan, V. (2024). Model-Informed Precision Dosing for Personalized Ustekinumab Treatment in Plaque Psoriasis. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16101295"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"DeBonis, J., Veiseh, O., and Igoshin, O.A. (2024). Uncovering the interleukin-12 pharmacokinetic desensitization mechanism and its consequences with mathematical modeling. CPT Pharmacomet. Syst. Pharmacol.","DOI":"10.1101\/2024.02.20.581191"},{"key":"ref_58","unstructured":"(2024, August 29). BOT PLUS. Available online: https:\/\/botplusweb.farmaceuticos.com\/."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","article-title":"Treatment goals for psoriasis: Should PASI 90 become the standard of care?","volume":"106","author":"Torres","year":"2015","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cpt.3357","article-title":"Extended Model-Informed Drug Development: Beyond Clinical Trials and Regulatory Approval","volume":"116","author":"Kamal","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cpt.659","article-title":"Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future","volume":"101","author":"Darwich","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dolan, J.G., Veazie, P.J., and Russ, A.J. (2013). Development and initial evaluation of a treatment decision dashboard. BMC Med. Inform. Decis. Mak., 13.","DOI":"10.1186\/1472-6947-13-51"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1208\/s12248-014-9632-5","article-title":"Dashboard systems: Implementing pharmacometrics from bench to bedside","volume":"16","author":"Mould","year":"2014","journal-title":"AAPS J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cpt.3285","article-title":"\u201cGetting the Dose Right\u201d\u2014Revisiting the Topic with Focus on Biologic Agents","volume":"116","author":"Mould","year":"2024","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/12\/1576\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:51:15Z","timestamp":1760115075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/12\/1576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["pharmaceutics16121576"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16121576","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}